Compare PSTG & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSTG | ILMN |
|---|---|---|
| Founded | 2009 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.0B | 20.4B |
| IPO Year | 2015 | 2000 |
| Metric | PSTG | ILMN |
|---|---|---|
| Price | $73.52 | $116.00 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 19 | 17 |
| Target Price | $92.58 | ★ $124.24 |
| AVG Volume (30 Days) | ★ 3.2M | 2.4M |
| Earning Date | 02-25-2026 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 4.15 | N/A |
| EPS | 0.38 | ★ 5.45 |
| Revenue | $3,483,782,000.00 | ★ $4,343,000,000.00 |
| Revenue This Year | $17.04 | $3.50 |
| Revenue Next Year | $16.42 | $6.30 |
| P/E Ratio | $194.45 | ★ $21.43 |
| Revenue Growth | ★ 13.18 | N/A |
| 52 Week Low | $34.51 | $68.70 |
| 52 Week High | $100.59 | $155.53 |
| Indicator | PSTG | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 50.82 | 29.45 |
| Support Level | $64.02 | $112.65 |
| Resistance Level | $76.84 | $119.92 |
| Average True Range (ATR) | 3.99 | 4.92 |
| MACD | 0.34 | -3.53 |
| Stochastic Oscillator | 62.44 | 8.70 |
Pure Storage Inc is a U.S.-based company that provides an enterprise data storage platform that transforms business through a dramatic increase in performance and reduction in complexity and costs. It generates revenue from two sources: product revenue, which includes the sale of integrated storage hardware and embedded operating system software; and subscription services revenue, which includes Evergreen Storage subscriptions, a unified subscription that includes Pure as-a-Service, Cloud Block Store, and Portworx. Subscription services revenue also includes professional services offerings such as installation and implementation consulting services.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.